WU
30
6
LMT
32
-12
KMX
64
6
EXR
60
3
EW
39
2
WHR
64
3
NKE
30
2
FITB
60
2
MU
36
5
HPE
61
6
ALL
51
8
RRC
59
-4
CAT
62
7
ROK
47
-8
HRL
41
2
OMC
61
6
ISRG
76
2
PDCO
38
3
SYY
49
2
PCAR
56
3
WU
30
6
LMT
32
-12
KMX
64
6
EXR
60
3
EW
39
2
WHR
64
3
NKE
30
2
FITB
60
2
MU
36
5
HPE
61
6
ALL
51
8
RRC
59
-4
CAT
62
7
ROK
47
-8
HRL
41
2
OMC
61
6
ISRG
76
2
PDCO
38
3
SYY
49
2
PCAR
56
3
Financhill
Back

Crinetics Pharmaceuticals 10K Form

Buy
56

CRNX
Crinetics Pharmaceuticals

Last Price:
56.06
Seasonality Move:
7.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CRNX News And Ratings

See the #1 stock for the next 7 days that we like better than CRNX

CRNX Financial Statistics

Sales & Book Value

Annual Sales: $4.01M
Cash Flow: $-63.35M
Price / Cash Flow: 0
Annual Sales: $10.30
Price / Book: 6.35

Profitability

EPS (TTM): -3.73000
Net Income (TTM): $-277.91M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Crinetics Pharmaceuticals Earnings Forecast

Key Crinetics Pharmaceuticals Financial Ratios

  • The Research & Development expenses have been 4,199.53% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CRNX is -5,345.85% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 1 years.

Crinetics Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CRNX
CUSIP: 22663K
Website: crinetics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CRNX Technical Analysis vs Fundamental Analysis

Buy
56
Crinetics Pharmaceuticals (CRNX) is a Buy

Is Crinetics Pharmaceuticals a Buy or a Sell?